Immunology has spent decades trying to calm the whole storm. The result is a cabinet full of drugs that work by broadly suppressing the immune system, trading one set of problems for another. ai3Bio, a biotech that launched from stealth last September with $48 million, is betting there is a more elegant way. Its plan is to find the one cell type that started the trouble, and quietly remove it from the party.
The target is the Th17 cell, a specific population of T-cells that drives inflammation in a range of autoimmune diseases. The company’s thesis is that eliminating these pathogenic cells in vivo could reset the immune system without the chronic, blanket immunosuppression that defines current treatments. It is a surgical strike, in theory. The question is whether the company’s two complementary platforms can deliver the payload with enough precision to make the economics of health,fewer side effects, potentially curative outcomes,add up.
A merger of platforms and geographies
ai3Bio did not start from a blank slate. It was formed by combining two predecessor biotechs: Corner Therapeutics, a Boston-area immunotherapy company, and Novasenta, a Pittsburgh-based firm focused on the tumor microenvironment [UPMC Enterprises]. The merger brought together distinct scientific approaches and geographic footprints. The Pittsburgh operation retained about a dozen former Novasenta employees, while approximately 15 people work at the Watertown, Massachusetts headquarters, for a total launch team of about 27 [Pittsburgh Post-Gazette, September 2026].
The combined entity is pursuing two technical paths to the same goal, a dual-platform strategy that spreads the risk.
- STARx. This platform uses a lipid nanoparticle to deliver mRNA into pathogenic Th17 cells. The mRNA is designed to trigger a targeted, anti-inflammatory self-destruct process inside the cell [World Today News, September 2026].
- T Deplete. This is an antibody-based approach that recruits the body’s own immune system to eliminate the Th17 cells [AllSci].
Both are designed for in-vivo use, aiming to selectively remove the bad actors while leaving the rest of the immune system intact. The initial disease targets are autoimmune disorders of the liver [MedCity News, October 2026].
The team behind the reset
The leadership team carries the heavy credentials typical of a venture-scale biotech, with a particular blend of academic depth and operational heft. The table below outlines the key players steering the company’s $48 million Series A toward the clinic.
| Role | Name | Key Background |
|---|---|---|
| CEO | Steven Altschuler | Repeat biotech entrepreneur; former CEO of Children’s Hospital of Philadelphia; co-founder of Spark Therapeutics [Yahoo Finance][PHILADELPHIA.Today]. |
| Scientific Co-Founder | Jonathan Kagan, MD, PhD | Professor at Harvard Medical School and Boston Children’s Hospital; scientific co-founder of Corner Therapeutics [MedCity News, October 2026]. |
| CTO | Michael Lyman, PhD | Drug-discovery veteran with experience bringing therapeutic antibodies into the clinic [ai3Bio]. |
| Chief Financial & Business Officer | Nick Seaver | Listed in the company’s launch announcement [Business Wire, September 2026]. |
Altschuler provides the seasoned operational leadership, while Kagan anchors the foundational immunology research. His work focuses on signal transduction in immune cells, and his postdoctoral training was under renowned immunologist Ruslan Medzhitov at Yale [eMedEvents, retrieved 2026]. This academic pedigree is a non-negotiable currency in early-stage biotech, helping to de-risk the core scientific premise for investors.
The scale of the immunosuppression market
The commercial rationale is straightforward. The global market for immunosuppressive drugs is massive, measured in tens of billions of dollars annually, supporting chronic treatments for conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These drugs are effective for many patients, but they come with significant costs: not just the price of the therapy itself, but the long-term healthcare burden of managing increased risks of infection and other complications.
ai3Bio’s bet is that a targeted, potentially curative approach could command a premium by reducing that downstream burden. The Series A funding, led by UPMC Enterprises and Ziff Capital Partners with participation from Cockrell Interests and Tanis Ventures, is earmarked for IND-enabling work, with first-in-human studies planned in autoimmune disease [Business Wire, September 2026][AllSci]. The backers are effectively funding the first major test of whether this selective depletion is more than a elegant concept.
The delivery problem
For all the promise of a targeted reset, the path is littered with formidable biological challenges. The immune system is a complex, adaptive network; removing one cell type might simply prompt another to take up the inflammatory mantle. The delivery mechanisms themselves are high-stakes engineering problems. Getting lipid nanoparticles or antibodies to hit only Th17 cells, and only the pathogenic ones, within the messy environment of a human body, is an immense hurdle. Any off-target effects could undermine the entire value proposition of safety and precision.
Furthermore, the company is entering a crowded field of autoimmune research, even if its specific mechanism is novel. Large pharma and other biotechs are constantly pursuing next-generation therapies. ai3Bio’s answer to these risks appears to be its dual-platform approach and its academic-founder depth. By attacking the problem with two different technologies, it hedges against the failure of one. And by anchoring its science in Kagan’s research, it aims to build a moat of biological insight that is harder to replicate quickly.
What the next 18 months must prove
The clock started with the September 2026 close. The capital gives the team of 27 roughly 18 to 24 months of runway to hit its preclinical milestones and prepare an Investigational New Drug (IND) application. The key watchpoints are clear: robust data showing selective depletion of Th17 cells in animal models, a clean safety profile, and the selection of a lead candidate to advance into the clinic.
A back-of-the-envelope calculation puts the pressure in perspective. With $48 million and 27 employees, the company’s burn rate is likely in the range of $2-$2.5 million per month, a typical figure for an early-stage biotech running lab operations and animal studies. That budget has to cover the parallel development of two platforms. The efficiency of that spend,how much definitive data each dollar produces,will determine if the next round is a competitive Series B or a down-round scramble.
Success for ai3Bio isn’t just about beating a lab benchmark. Its incumbent is the entire class of broad immunosuppressants, drugs like Humira or Enbrel. To displace them, it must prove that its surgical strike is not only as effective at halting disease, but that the avoided costs of chronic immunosuppression,the infections, the monitoring, the reduced quality of life,are worth the undoubtedly high price of a novel, targeted therapy. It is a bet on precision as the ultimate form of economic efficiency in medicine.
Sources
- [Business Wire, September 2026] ai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Root | https://www.businesswire.com/news/home/20260929289122/en/ai3Bio-Launches-with-$48-Million-in-Series-A-Funding-to-Reset-the-Immune-System-at-Its-Root
- [Pittsburgh Post-Gazette, September 2026] Pittsburgh biotech partners with Boston-area company, forming new startup | https://www.post-gazette.com/business/healthcare-business/2026/09/29/pittsburgh-biotech-upmc-enterprises-partners-boston-new-company/stories/202609290028
- [MedCity News, October 2026] Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System | https://medcitynews.com/2026/10/immune-reset-startup-ai3bio-immunology-inflammation-autoimmune-liver-disease-t-cell-th17-il-17-cgas-sting/
- [AllSci] ai3Bio series A funding | https://allsci.com/news/biotech/ai3bio-series-a-funding-th17-launches-with-usd/
- [World Today News, September 2026] ai3Bio launches with $48 million in Series A funding | https://worldtoday.news/ai3bio-launches-with-48-million-in-series-a-funding-to-reset-the-immune-system-at-its-root/
- [UPMC Enterprises] Advancing Breakthrough Science: UPMC Enterprises and the Launch of ai3Bio | https://enterprises.upmc.com/resources/insights/advancing-breakthrough-science-upmc-enterprises-and-the-launch-of-ai3-bio/
- [Yahoo Finance] ai3Bio Launches with $48 Million in Series A Funding | https://finance.yahoo.com/healthcare/articles/ai3bio-launches-48-million-series-130000660.html
- [PHILADELPHIA.Today] Steven Altschuler co-founded Spark Therapeutics | https://philadelphia.today/
- [eMedEvents, retrieved 2026] Jonathan C. Kagan, Associate Professor | https://www.emedevents.com/speaker-profile/jonathan-c-kagan
- [ai3Bio] Company website | https://ai3.bio/